Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...

The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ...

StockNews.com lowered shares of Innoviva (NASDAQ:INVA – Free Report) from a buy rating to a hold rating in a report published on Thursday. Innoviva Price Performance Shares of INVA opened at $18.08 on ...

Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and ...

Sales of Advair/Seretide and Anoro Ellipta fell 2% each. Revlar/Breo Ellipta sales declined 5%. The decline in vaccine sales was primarily due to lower sales of its RSV vaccine Arexvy. The figure ...

Its biggest competitor is GSK, which also has a new dual bronchodilator Anoro Ellipta. Results from GSK's combination have underwhelmed until now, and failed to show superiority to the older ...

Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva ...

ACPN Laments Poor Implementation Of Zero Duty On Drugs The surge in the cost of critical drugs for treatment and managing BP ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...